Opinion of the Transparency Council – cetuximab B.4
At its meeting on 26 August 2024, the Transparency Council adopted opinion No. 135/2024 on the transfer of the active substance cetuximab from the drug program: B.4 “Treatment of patients with colorectal cancer (ICD-10: C18-20)” to the catalog of reimbursable drugs in chemotherapy.